DE PAOLI, LORENZO
 Distribuzione geografica
Continente #
EU - Europa 376
NA - Nord America 261
AS - Asia 96
AF - Africa 1
SA - Sud America 1
Totale 735
Nazione #
US - Stati Uniti d'America 254
IE - Irlanda 133
SE - Svezia 71
DE - Germania 68
IT - Italia 58
HK - Hong Kong 32
UA - Ucraina 27
SG - Singapore 22
IN - India 18
CN - Cina 16
FI - Finlandia 8
CA - Canada 7
IR - Iran 7
CZ - Repubblica Ceca 3
AL - Albania 2
GB - Regno Unito 2
NL - Olanda 2
CH - Svizzera 1
EG - Egitto 1
FR - Francia 1
LA - Repubblica Popolare Democratica del Laos 1
PE - Perù 1
Totale 735
Città #
Dublin 133
Jacksonville 49
Chandler 37
Hong Kong 32
Piemonte 19
Dearborn 18
Bremen 15
Lawrence 15
Princeton 15
Singapore 14
Grafing 13
Boardman 12
Wilmington 12
Beijing 7
Munich 7
Cassano Magnago 4
Helsinki 4
San Mateo 4
Toronto 4
Turin 4
Ashburn 3
Brno 3
Houston 3
Novara 3
Woodbridge 3
Zanjan 3
Ann Arbor 2
Berlin 2
Castellazzo Bormida 2
Guangzhou 2
Hefei 2
Monza 2
Nanjing 2
Parma 2
Tirana 2
Vercelli 2
West Jordan 2
Altavilla Monferrato 1
Andover 1
Arona 1
Biella 1
Cairo 1
Düsseldorf 1
Fairfield 1
Guiyang 1
Leawood 1
Lima 1
London 1
Milan 1
Montréal 1
Mumbai 1
Nanchang 1
Naples 1
Ottawa 1
Seattle 1
Strasbourg 1
Trani 1
Vientiane 1
Villavesco 1
Voghera 1
Winnipeg 1
Zhengzhou 1
Zurich 1
Totale 484
Nome #
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 88
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 69
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 66
Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication 65
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 64
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 57
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 54
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma 53
RICHTER SYNDROME: FROM MOLECULAR GENETIC TO THERAPEUTIC STRATEGIES 51
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 43
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy 39
Radiotherapy in COVID-19 patient affected by multiple myeloma: A case report 36
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 27
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 27
Totale 766
Categoria #
all - tutte 5.293
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.293


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202068 0 0 0 0 0 0 18 5 8 28 9 0
2020/202167 8 2 9 0 10 4 9 0 12 2 11 0
2021/2022101 1 2 2 14 4 0 15 2 4 11 21 25
2022/2023299 17 15 29 5 21 26 7 21 142 1 9 6
2023/202494 10 8 8 2 11 2 21 1 0 5 3 23
2024/202546 7 1 8 5 10 13 2 0 0 0 0 0
Totale 766